Century Therapeutics Stock Performance
| IPSC Stock | USD 1.75 0.04 2.23% |
Century Therapeutics holds a performance score of 20 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.4, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Century Therapeutics will likely underperform. Use Century Therapeutics sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Century Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Century Therapeutics are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Century Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Pluristyx Launches Organoid COMMONS, Uniting Industry Leaders to Revolutionize Drug Discovery | 12/02/2025 |
2 | Disposition of 463 shares by Pfeiffenberger Brent of Century Therapeutics at 0.526 subject to Rule 16b-3 | 12/10/2025 |
3 | Acquisition by Chad Cowan of 58060 shares of Century Therapeutics at 0.8483 subject to Rule 16b-3 | 12/22/2025 |
4 | Chad Cowan Buys 58,060 Shares of Century Therapeutics Stock - MarketBeat | 12/29/2025 |
5 | Disposition of 1611 shares by Chad Cowan of Century Therapeutics at 0.995 subject to Rule 16b-3 | 01/02/2026 |
6 | Fast-paced Momentum Stock Century Therapeutics Is Still Trading at a Bargain | 01/07/2026 |
7 | Century Therapeutics Secures Oversubscribed 135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1... | 01/08/2026 |
8 | Century Therapeutics Highlights Progress in Immune-Evasive Cell Therapies - TipRanks | 01/12/2026 |
9 | Deep Track Capital, LPs Strategic Acquisition of Century Therap - GuruFocus | 01/22/2026 |
10 | REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools | 01/28/2026 |
11 | Acquisition by Carr Douglas of 225000 shares of Century Therapeutics at 1.84 subject to Rule 16b-3 | 02/02/2026 |
12 | Pluristyx and Solesis Launch First-of-its-Kind PluriForm-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection | 02/05/2026 |
13 | Century Therapeutics, Inc. Short Interest Update | 02/13/2026 |
| Begin Period Cash Flow | 49.3 M | |
| Total Cashflows From Investing Activities | 47.5 M |
Century Therapeutics Relative Risk vs. Return Landscape
If you would invest 48.00 in Century Therapeutics on November 16, 2025 and sell it today you would earn a total of 127.00 from holding Century Therapeutics or generate 264.58% return on investment over 90 days. Century Therapeutics is currently generating 2.5633% in daily expected returns and assumes 9.8044% risk (volatility on return distribution) over the 90 days horizon. In different words, 88% of stocks are less volatile than Century, and 49% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Century Therapeutics Target Price Odds to finish over Current Price
The tendency of Century Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.75 | 90 days | 1.75 | about 22.02 |
Based on a normal probability distribution, the odds of Century Therapeutics to move above the current price in 90 days from now is about 22.02 (This Century Therapeutics probability density function shows the probability of Century Stock to fall within a particular range of prices over 90 days) .
Century Therapeutics Price Density |
| Price |
Predictive Modules for Century Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Century Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Century Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Century Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Century Therapeutics is not an exception. The market had few large corrections towards the Century Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Century Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Century Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.10 | |
β | Beta against Dow Jones | 1.40 | |
σ | Overall volatility | 0.70 | |
Ir | Information ratio | 0.22 |
Century Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Century Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Century Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Century Therapeutics is way too risky over 90 days horizon | |
| Century Therapeutics may become a speculative penny stock | |
| Century Therapeutics appears to be risky and price may revert if volatility continues | |
| Century Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.59 M. Net Loss for the year was (126.57 M) with profit before overhead, payroll, taxes, and interest of 7.99 M. | |
| Century Therapeutics currently holds about 378.76 M in cash with (110.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Century Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Century Therapeutics, Inc. Short Interest Update |
Century Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Century Stock often depends not only on the future outlook of the current and potential Century Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Century Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 78.6 M | |
| Cash And Short Term Investments | 189.3 M |
Century Therapeutics Fundamentals Growth
Century Stock prices reflect investors' perceptions of the future prospects and financial health of Century Therapeutics, and Century Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Century Stock performance.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0447 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 65.95 M | ||||
| Shares Outstanding | 87.41 M | ||||
| Price To Earning | 86.08 X | ||||
| Price To Book | 0.87 X | ||||
| Price To Sales | 1.35 X | ||||
| Revenue | 6.59 M | ||||
| Gross Profit | 7.99 M | ||||
| EBITDA | (111.47 M) | ||||
| Net Income | (126.57 M) | ||||
| Cash And Equivalents | 378.76 M | ||||
| Cash Per Share | 6.43 X | ||||
| Total Debt | 53.83 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.79 X | ||||
| Book Value Per Share | 2.04 X | ||||
| Cash Flow From Operations | (110.14 M) | ||||
| Earnings Per Share | (0.31) X | ||||
| Market Capitalization | 152.96 M | ||||
| Total Asset | 353.22 M | ||||
| Retained Earnings | (782.34 M) | ||||
| Working Capital | 64.27 M | ||||
About Century Therapeutics Performance
By analyzing Century Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Century Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Century Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Century Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.37) | |
| Return On Capital Employed | (0.71) | (0.75) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.90) | (0.86) |
Things to note about Century Therapeutics performance evaluation
Checking the ongoing alerts about Century Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Century Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Century Therapeutics is way too risky over 90 days horizon | |
| Century Therapeutics may become a speculative penny stock | |
| Century Therapeutics appears to be risky and price may revert if volatility continues | |
| Century Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.59 M. Net Loss for the year was (126.57 M) with profit before overhead, payroll, taxes, and interest of 7.99 M. | |
| Century Therapeutics currently holds about 378.76 M in cash with (110.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Century Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Century Therapeutics, Inc. Short Interest Update |
- Analyzing Century Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Century Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Century Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Century Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Century Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Century Therapeutics' stock. These opinions can provide insight into Century Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Century Stock analysis
When running Century Therapeutics' price analysis, check to measure Century Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Century Therapeutics is operating at the current time. Most of Century Therapeutics' value examination focuses on studying past and present price action to predict the probability of Century Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Century Therapeutics' price. Additionally, you may evaluate how the addition of Century Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |